<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="8969">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02990195</url>
  </required_header>
  <id_info>
    <org_study_id>35RC16_8914_RESCUE</org_study_id>
    <nct_id>NCT02990195</nct_id>
  </id_info>
  <brief_title>Restoring the Beneficial Effects of Enterohepatic Bile Salt Signalling by Chyme Reinfusion in Patients With a Double Enterostomy</brief_title>
  <acronym>RESCUE</acronym>
  <official_title>Restoring the Beneficial Effects of Enterohepatic Bile Salt Signalling by Chyme Reinfusion in Patients With a Double Enterostomy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rennes University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Rennes University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Multicentre prospective human experimental study to determine the effect of chyme reinfusion
      in patients with a double enterostomy on plasma levels of Fibroblast Growth Factor (FGF19)
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients supported by chyme reinfusion will be followed for 3 days pre chyme reinfusion and
      for 7 weeks during chyme reinfusion. Three days prior chyme reinfusion, baseline
      characteristics will be determined, an ileal biopsy, blood, chyme and urine will be
      collected. Furthermore, blood, chyme, faeces and urine will be collected at the first day of
      chime reinfusion. These materials will be collected again at week 1, 3, 5 and 7 weeks after
      initiation of chyme reinfusion. A second ileal biopsy will be performed at week 3.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of chyme reinfusion in patients with a double enterostomy on plasma levels of FGF19</measure>
    <time_frame>Week 7</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of chyme reinfusion in patients with a double enterostomy on plasma bile salt levels</measure>
    <time_frame>Week 7</time_frame>
    <description>Measurement of bile salt</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of 7-alpha-hydroxy-4-cholesten-3-one (C4) plasma levels</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of bile salt composition in plasma</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of microbiotic profiling</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of citrulline plasma levels</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of intestinal-fatty acid binding protein (I-FABP) plasma levels</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of smooth muscle specific (SM) 22 plasma levels</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of chyme reinfusion in patients with a double enterostomy on liver function</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of lipopolysaccharide binding protein (LBP) plasma levels</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma levels of inflammatory cytokines interleukin-6 (IL-6)</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Assessment of plasma levels of tumor necrosis factor-alpha (TNF-alpha)</measure>
    <time_frame>Week 7</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Double Enterostomy</condition>
  <arm_group>
    <arm_group_label>Double enterostomy</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Chyme reinfusion</intervention_name>
    <arm_group_label>Double enterostomy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age equal or above 18 years old

          -  Temporary double enterostomy treated by chyme reinfusion as a routine primary care

          -  Downstream bowel of at least 25 cm of healthy small bowel, accessible by a stoma, and
             suitable for chyme reinfusion and ileal biopsy

          -  In case of enterocutaneous fistula, diagnosis of fistula origin and localization
             confirmed by additional medical imaging (computerized tomography/fistulography)

          -  Written informed consent.

        Exclusion Criteria:

          -  Patients with a mental disability

          -  Pregnancy or lactation

          -  Hepatocellular carcinoma

          -  Blood coagulation disorders

          -  Shock of any cause

          -  Patients subject to major legal protection (safeguarding justice, guardianship,
             trusteeship), persons deprived of liberty
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ronan Thibault, MD, PhD</last_name>
    <phone>33 2 99 28 96 46</phone>
    <email>ronan.thibault@chu-rennes.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Rennes</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ronan Thibault, MD, PhD</last_name>
      <phone>+33 2 99 28 96 46</phone>
      <email>ronan.thibault@chu-rennes.fr</email>
    </contact>
    <investigator>
      <last_name>Laurent Sulpice, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Aude Merdrignac, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Clinique Saint Yves</name>
      <address>
        <city>Rennes</city>
        <zip>35033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Denis Picot, MD</last_name>
      <phone>+33 (0)2 99 26 26 17</phone>
      <email>picot@clinique-styves.fr</email>
    </contact>
    <investigator>
      <last_name>Sabrina Layec, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Laurence Dussaulx, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Florence Trivin, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Maastricht University, Research Laboratories at the Department of General Surgery</name>
      <address>
        <city>Maastricht</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kiran V.K. Koelfat, MD MSc</last_name>
      <phone>+31433881251</phone>
      <email>k.koelfat@maastrichtuniversity.nl</email>
    </contact>
    <investigator>
      <last_name>Frank G. Schaap, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Steven W. M. Olde Damink, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <lastchanged_date>January 3, 2017</lastchanged_date>
  <firstreceived_date>December 6, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Bile Acids and Salts</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
